Primary BSI type was classified as infective endocarditis (using the modified Duke criteria), uncomplicated bacteremia, or complicated bacteremia (5, 6) . Uncomplicated bacteremia was defined by the isolation of mecA-MSSA or MRSA from blood cultures in patients without endocarditis, without implanted prostheses, having negative follow-up blood cultures obtained 2 to 4 days after the index culture, defervescence within 72 h of initiating effective therapy, and no evidence of metastatic sites of infection (5, 7) . Patients not meeting the definition for uncomplicated BSI or infective endocarditis were classified as complicated BSI (5, 6) . The source of bacteremia and severity of illness (Pitt bacteremia score) were categorized as previously described (8, 9) . Clinical failure was a composite endpoint that included 30-day mortality, persistent bacteremia (Ն7 days), and/or change of intravenous antibiotic(s) or addition of a second antibiotic targeted against mecA-MSSA or MRSA necessitated by a lack of infection resolution. Secondary outcomes of interest included length of stay and nephrotoxicity, as defined by the vancomycin consensus guidelines (10) . This study was approved by the Wheaton Franciscan Healthcare institutional review board and was conducted in accordance with the Declaration of Helsinki. Continuous variables were summarized using the mean and standard deviation (SD) or the median and interquartile range (IQR). Two-sample t tests or Wilcoxon rank sum tests were used to compare the two groups. Categorical variables were summarized using frequencies and percentages and compared between the two groups using the likelihood ratio 2 or Fisher's exact test.
Twenty-six patients with mecA-MSSA BSI were identified. Of these, nine patients were excluded on the basis of: age (n ϭ 1), irretrievable data in the medical record (n ϭ 7), and insufficient follow-up data (n ϭ 1). The 17 remaining mecA-MSSA patients were successfully matched with a MRSA BSI comparator (n ϭ 34 total patients). No major differences between the two study groups in baseline characteristics were observed ( Table 1) . The proportion of patients with renal disease, a strong predictor of mortality in S. aureus bacteremia, was 29.4% in both groups; however, there were more patients on intermittent hemodialysis in the MRSA group (3 versus 1, respectively; P ϭ 0.601) (2) . All patients in the study were treated by an infectious diseases physician, and 94.1% of the patients received empirical vancomycin therapy in both groups.
Patients with mecA-MSSA BSI were more likely to experience clinical failure than those with MRSA BSI (58.8% versus 11.8%, respectively; P ϭ 0.010), and patients with mecA-MSSA BSI tended to experience persistent bacteremia (35.3% versus 11.8%, respectively; P ϭ 0.225). Salvage antibiotic therapy was employed in 10 (58.8%) and 2 (11.8%) of patients in the mecA-MSSA and MRSA groups, respectively ( Table 2) . Combination antibiotic therapy was used as salvage therapy in all of these cases, with the exception of one patient with mecA-MSSA BSI who received ceftaroline monotherapy. The median length of stay and infection-related length of stay both trended longer for the mecA-MSSA group than for the MRSA group. Nephrotoxicity was observed more frequently in the mecA-MSSA group than in the MRSA group (23.5% versus 0%, respectively; P ϭ 0.100), despite similar rates of renal disease between groups.
In the current study, patients with mecA-MSSA bacteremia experienced clinical failure more often than matched patients with MRSA bacteremia. Failure was primarily driven by persistent bacteremia in the mecA-MSSA group, but clinical outcomes, such as mortality and length of stay, were similar between groups. Nearly all patients who experienced failure had complicated BSI. Given the well-matched groups, this difference in clinical failure is unlikely due to host-level factors, although it could be a result of an unmeasured host factor. It remains more plausible, based on our observations, that either vancomycin monotherapy contributed to the delayed bacterial clearance observed in the mecA-MSSA group, or intrinsic virulence differences between these two strains of S. aureus led to longer durations of bacteremia in the mecA-MSSA group. These results expose yet another limitation of vancomycin monotherapy for the treatment of MRSA bacteremia.
Almost all mecA-MSSA patients received vancomycin initially, likely because the CLSI recommends reporting mecA-positive S. aureus as cefoxitin resistant. During the study (13) . The cefoxitin-susceptible phenotype of the mecA-MSSA isolates may represent both reduced expression of PBP4 and vancomycin tolerance; interestingly, the median vancomycin MIC was higher in the mecA-MSSA group than the MRSA group. Given that the majority of patients in both groups received initial therapy with vancomycin, the difference in vancomycin MICs between groups may also explain the observed difference in persistent bacteremia between groups. Our study is limited by its retrospective design, small sample, and restriction to a single health system in one geographic area of the United States. Additionally, bacterial isolates were not secured for additional laboratory analyses, nor did we have daptomycin and ceftaroline MICs for these isolates. However, the collected microbiological data represent what is available to clinicians, and this is the first clinical evaluation of mecA-MSSA to include more than two patients from a single center (1, 14) . We believe these results should prove informative for clinicians confronted with mecA-MSSA BSI. It is clear from these data that the treatment of mecA-MSSA poses a unique challenge for infectious diseases clinicians and requires additional attention.
In summation, mecA PCR testing and the potential for a discrepancy between genotypic and phenotypic cefoxitin resistance results among S. aureus isolates have further complicated the treatment of S. aureus BSI. The description of mecA-positive S. aureus as cefoxitin resistant should be reevaluated, as this may predispose patients to vancomycin therapy, especially if physicians are notified of mecA PCR results before susceptibility results. Our data suggest that vancomycin monotherapy for mecA-MSSA BSI may place patients at risk for clinical failure.
